Phase i dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors

F. Caponigro, D. Lorusso, G. Fornari, C. Barone, M. Merlano, M. Airoldi, M. Schena, R. MacArthur, Steven D Weitman, M. G. Jannuzzo, S. Crippa, F. Fiorentini, A. Petroccione, S. Comis

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose Brostallicin is a DNA minor groove binder which shows enhanced antitumor activity in cells which are resistant to several anticancer agents due to their high glutathione S-transferase (GST)/glutathione content. Phase I and II clinical trials of single-agent brostallicin have shown that myelotoxicity is the dose-limiting toxicity (DLT), while hints of antitumor activity were mainly observed in soft tissue sarcoma. Preclinical studies showing a more than additive antitumor effect of the cisplatin-brostallicin combination paved the way to clinical combination studies. In particular, we set up the first clinical combination study of brostallicin and cisplatin in patients with advanced solid tumors. This study was to be followed by a phase II study in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN). Methods Escalating doses of brostallicin were administered in combination with a fixed dose of cisplatin (75 mg/ m2) in patients with recurrent or metastatic advanced solid tumors who had previously received a cumulative dose of cisplatin not higher than 475 mg/m2. The recommended dose of brostallicin was expanded in order to have a better estimate of antitumor activity and to better define the safety profile of the combination. Results Twenty-one patients were treated. Two DLTs (grade 3 fatigue and febrile neutropenia) were observed at dose level 3 (brostallicin 9 mg/m2). Dose level 2 (brostallicin 7 mg/m2 and cisplatin 75 mg/m2) was recommended for future phase II studies. Main toxicity was hematologic; in fact, only 1 patient out of 21 did not develop neutropenia and only 2 patients did not have thrombocytopenia. Grade 3-4 neutropenia was observed in 90.5% of patients, grade 3-4 thrombocytopenia in 38.1%, grade 3-4 anemia in 23.8%. The cycle 1 nadir (ANC < 500 × 109/L) for neutrophils was Day 14 (median; range 11-17) with recovery to an ANC of <1,500 3.5 days after nadir (median; range 2-4) at dose level 3. The cycle 1 nadir (median of 51,000 × 109/ L) for platelets occurred on Day 13 (median; range 10-15) with recovery to a platelet count of >100,000 4 days after nadir (median; range 2-8). No objective responses were observed, but seven patients had a long lasting (>18 weeks) stable disease. Conclusions Further studies of the combination of brostallicin and cisplatin are warranted.

Original languageEnglish (US)
Pages (from-to)389-394
Number of pages6
JournalCancer Chemotherapy and Pharmacology
Volume66
Issue number2
DOIs
StatePublished - Jul 2010
Externally publishedYes

Fingerprint

Cisplatin
Binders
Tumors
Neoplasms
Neutropenia
Toxicity
brostallicin
Febrile Neutropenia
Phase II Clinical Trials
Clinical Trials, Phase I
Glutathione Transferase
Sarcoma
Thrombocytopenia
Antineoplastic Agents
Fatigue
Glutathione
Anemia
Fatigue of materials
Tissue
Safety

Keywords

  • Brostallicin
  • Cisplatin
  • Phase I
  • Solid tumors

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Toxicology

Cite this

Phase i dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors. / Caponigro, F.; Lorusso, D.; Fornari, G.; Barone, C.; Merlano, M.; Airoldi, M.; Schena, M.; MacArthur, R.; Weitman, Steven D; Jannuzzo, M. G.; Crippa, S.; Fiorentini, F.; Petroccione, A.; Comis, S.

In: Cancer Chemotherapy and Pharmacology, Vol. 66, No. 2, 07.2010, p. 389-394.

Research output: Contribution to journalArticle

Caponigro, F, Lorusso, D, Fornari, G, Barone, C, Merlano, M, Airoldi, M, Schena, M, MacArthur, R, Weitman, SD, Jannuzzo, MG, Crippa, S, Fiorentini, F, Petroccione, A & Comis, S 2010, 'Phase i dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors', Cancer Chemotherapy and Pharmacology, vol. 66, no. 2, pp. 389-394. https://doi.org/10.1007/s00280-009-1175-6
Caponigro, F. ; Lorusso, D. ; Fornari, G. ; Barone, C. ; Merlano, M. ; Airoldi, M. ; Schena, M. ; MacArthur, R. ; Weitman, Steven D ; Jannuzzo, M. G. ; Crippa, S. ; Fiorentini, F. ; Petroccione, A. ; Comis, S. / Phase i dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors. In: Cancer Chemotherapy and Pharmacology. 2010 ; Vol. 66, No. 2. pp. 389-394.
@article{ed1ff95252e34a419bbdbecf3a524ff0,
title = "Phase i dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors",
abstract = "Purpose Brostallicin is a DNA minor groove binder which shows enhanced antitumor activity in cells which are resistant to several anticancer agents due to their high glutathione S-transferase (GST)/glutathione content. Phase I and II clinical trials of single-agent brostallicin have shown that myelotoxicity is the dose-limiting toxicity (DLT), while hints of antitumor activity were mainly observed in soft tissue sarcoma. Preclinical studies showing a more than additive antitumor effect of the cisplatin-brostallicin combination paved the way to clinical combination studies. In particular, we set up the first clinical combination study of brostallicin and cisplatin in patients with advanced solid tumors. This study was to be followed by a phase II study in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN). Methods Escalating doses of brostallicin were administered in combination with a fixed dose of cisplatin (75 mg/ m2) in patients with recurrent or metastatic advanced solid tumors who had previously received a cumulative dose of cisplatin not higher than 475 mg/m2. The recommended dose of brostallicin was expanded in order to have a better estimate of antitumor activity and to better define the safety profile of the combination. Results Twenty-one patients were treated. Two DLTs (grade 3 fatigue and febrile neutropenia) were observed at dose level 3 (brostallicin 9 mg/m2). Dose level 2 (brostallicin 7 mg/m2 and cisplatin 75 mg/m2) was recommended for future phase II studies. Main toxicity was hematologic; in fact, only 1 patient out of 21 did not develop neutropenia and only 2 patients did not have thrombocytopenia. Grade 3-4 neutropenia was observed in 90.5{\%} of patients, grade 3-4 thrombocytopenia in 38.1{\%}, grade 3-4 anemia in 23.8{\%}. The cycle 1 nadir (ANC < 500 × 109/L) for neutrophils was Day 14 (median; range 11-17) with recovery to an ANC of <1,500 3.5 days after nadir (median; range 2-4) at dose level 3. The cycle 1 nadir (median of 51,000 × 109/ L) for platelets occurred on Day 13 (median; range 10-15) with recovery to a platelet count of >100,000 4 days after nadir (median; range 2-8). No objective responses were observed, but seven patients had a long lasting (>18 weeks) stable disease. Conclusions Further studies of the combination of brostallicin and cisplatin are warranted.",
keywords = "Brostallicin, Cisplatin, Phase I, Solid tumors",
author = "F. Caponigro and D. Lorusso and G. Fornari and C. Barone and M. Merlano and M. Airoldi and M. Schena and R. MacArthur and Weitman, {Steven D} and Jannuzzo, {M. G.} and S. Crippa and F. Fiorentini and A. Petroccione and S. Comis",
year = "2010",
month = "7",
doi = "10.1007/s00280-009-1175-6",
language = "English (US)",
volume = "66",
pages = "389--394",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Phase i dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors

AU - Caponigro, F.

AU - Lorusso, D.

AU - Fornari, G.

AU - Barone, C.

AU - Merlano, M.

AU - Airoldi, M.

AU - Schena, M.

AU - MacArthur, R.

AU - Weitman, Steven D

AU - Jannuzzo, M. G.

AU - Crippa, S.

AU - Fiorentini, F.

AU - Petroccione, A.

AU - Comis, S.

PY - 2010/7

Y1 - 2010/7

N2 - Purpose Brostallicin is a DNA minor groove binder which shows enhanced antitumor activity in cells which are resistant to several anticancer agents due to their high glutathione S-transferase (GST)/glutathione content. Phase I and II clinical trials of single-agent brostallicin have shown that myelotoxicity is the dose-limiting toxicity (DLT), while hints of antitumor activity were mainly observed in soft tissue sarcoma. Preclinical studies showing a more than additive antitumor effect of the cisplatin-brostallicin combination paved the way to clinical combination studies. In particular, we set up the first clinical combination study of brostallicin and cisplatin in patients with advanced solid tumors. This study was to be followed by a phase II study in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN). Methods Escalating doses of brostallicin were administered in combination with a fixed dose of cisplatin (75 mg/ m2) in patients with recurrent or metastatic advanced solid tumors who had previously received a cumulative dose of cisplatin not higher than 475 mg/m2. The recommended dose of brostallicin was expanded in order to have a better estimate of antitumor activity and to better define the safety profile of the combination. Results Twenty-one patients were treated. Two DLTs (grade 3 fatigue and febrile neutropenia) were observed at dose level 3 (brostallicin 9 mg/m2). Dose level 2 (brostallicin 7 mg/m2 and cisplatin 75 mg/m2) was recommended for future phase II studies. Main toxicity was hematologic; in fact, only 1 patient out of 21 did not develop neutropenia and only 2 patients did not have thrombocytopenia. Grade 3-4 neutropenia was observed in 90.5% of patients, grade 3-4 thrombocytopenia in 38.1%, grade 3-4 anemia in 23.8%. The cycle 1 nadir (ANC < 500 × 109/L) for neutrophils was Day 14 (median; range 11-17) with recovery to an ANC of <1,500 3.5 days after nadir (median; range 2-4) at dose level 3. The cycle 1 nadir (median of 51,000 × 109/ L) for platelets occurred on Day 13 (median; range 10-15) with recovery to a platelet count of >100,000 4 days after nadir (median; range 2-8). No objective responses were observed, but seven patients had a long lasting (>18 weeks) stable disease. Conclusions Further studies of the combination of brostallicin and cisplatin are warranted.

AB - Purpose Brostallicin is a DNA minor groove binder which shows enhanced antitumor activity in cells which are resistant to several anticancer agents due to their high glutathione S-transferase (GST)/glutathione content. Phase I and II clinical trials of single-agent brostallicin have shown that myelotoxicity is the dose-limiting toxicity (DLT), while hints of antitumor activity were mainly observed in soft tissue sarcoma. Preclinical studies showing a more than additive antitumor effect of the cisplatin-brostallicin combination paved the way to clinical combination studies. In particular, we set up the first clinical combination study of brostallicin and cisplatin in patients with advanced solid tumors. This study was to be followed by a phase II study in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN). Methods Escalating doses of brostallicin were administered in combination with a fixed dose of cisplatin (75 mg/ m2) in patients with recurrent or metastatic advanced solid tumors who had previously received a cumulative dose of cisplatin not higher than 475 mg/m2. The recommended dose of brostallicin was expanded in order to have a better estimate of antitumor activity and to better define the safety profile of the combination. Results Twenty-one patients were treated. Two DLTs (grade 3 fatigue and febrile neutropenia) were observed at dose level 3 (brostallicin 9 mg/m2). Dose level 2 (brostallicin 7 mg/m2 and cisplatin 75 mg/m2) was recommended for future phase II studies. Main toxicity was hematologic; in fact, only 1 patient out of 21 did not develop neutropenia and only 2 patients did not have thrombocytopenia. Grade 3-4 neutropenia was observed in 90.5% of patients, grade 3-4 thrombocytopenia in 38.1%, grade 3-4 anemia in 23.8%. The cycle 1 nadir (ANC < 500 × 109/L) for neutrophils was Day 14 (median; range 11-17) with recovery to an ANC of <1,500 3.5 days after nadir (median; range 2-4) at dose level 3. The cycle 1 nadir (median of 51,000 × 109/ L) for platelets occurred on Day 13 (median; range 10-15) with recovery to a platelet count of >100,000 4 days after nadir (median; range 2-8). No objective responses were observed, but seven patients had a long lasting (>18 weeks) stable disease. Conclusions Further studies of the combination of brostallicin and cisplatin are warranted.

KW - Brostallicin

KW - Cisplatin

KW - Phase I

KW - Solid tumors

UR - http://www.scopus.com/inward/record.url?scp=77953053338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953053338&partnerID=8YFLogxK

U2 - 10.1007/s00280-009-1175-6

DO - 10.1007/s00280-009-1175-6

M3 - Article

C2 - 20480279

AN - SCOPUS:77953053338

VL - 66

SP - 389

EP - 394

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 2

ER -